VivoSeq
Other

Viremia

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Viremia is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

60/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated2 · 40%
Withdrawn1 · 20%

Clinical Trials

Trial Activity

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
Completed·GGermans Trias i Pujol Hospital·Phase 3·NCT01034917·43 enrolled
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT00855413·15 enrolled
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
Completed·—·Phase 2·NCT02542852·10 enrolled
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Terminated·AANRS, Emerging Infectious Diseases·Phase 3·NCT02247687·4 enrolled
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT05700630

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)